Evidence map›Paper›PMID 31764806›Full record

ArticleMedicine2019

Use of sacubitril/valsartan in Marfan syndrome-related cardiomyopathy: The first case report.

Silvia Spoto, Emanuele Valeriani, Luciana Locorriere, Giuseppina Beretta Anguissola, Angelo Lauria Pantano, Francesca Terracciani, Maria Caterina Bono, Sebastiano Costantino, Massimo Ciccozzi, Silvia Angeletti

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Silvia SpotoInternal Medicine Department, University Campus Bio-Medico of Rome, Rome.
Emanuele ValerianiInternal Medicine Department, University G. D'Annunzio, Chieti.
Luciana LocorriereInternal Medicine Department, University Campus Bio-Medico of Rome, Rome.
Giuseppina Beretta AnguissolaInternal Medicine Department, University Campus Bio-Medico of Rome, Rome.
Angelo Lauria PantanoInternal Medicine Department, University Campus Bio-Medico of Rome, Rome.
Francesca TerraccianiCardiology Department.
Maria Caterina BonoCardiology Department.
Sebastiano CostantinoInternal Medicine Department, University Campus Bio-Medico of Rome, Rome.
Massimo CiccozziUnit of Medical Statistic and Molecular Epidemiology.
Silvia AngelettiUnit of Clinical Laboratory Science, University Campus Bio-Medico of Rome, Rome, Italy.
Università Campus Bio-Medico · ITInstitute of Cardiology · PLStatistical Service · CYUniversity of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMarfan syndrome is a rare cause of heart failure due to primary or secondary cardiomyopathy. Recently, sacubitril/valsartan-an angiotensin receptor blocker-neprilysin inhibitor-has been added in clinical practice as a standard therapy for heart failure. To our knowledge, there are no data on sacubitril/valsartan's effects on cardiovascular outcomes in patients with Marfan syndrome. PATIENT CONCERNS: A 24-year-old man was admitted to our Internal Medicine Department due to dyspnea, ascites, and leg swelling. Arterial blood gas analysis revealed severe hypoxemia with respiratory and metabolic alkalosis. Hilar congestion was highlighted on chest x-ray. DIAGNOSES: Recurrent acute decompensated heart failure with reduced ejection fraction despite optimal medical therapy in Marfan-related cardiomyopathy. INTERVENTIONS AND OUTCOMES: Sacubitril/valsartan was added to optimal medical therapy after hemodynamic stabilization allowing progressive clinical, laboratoristic, and echocardiographic improvement. Patient maintained a free survival from heart failure and a good quality of life until 9-month follow-up. LESSONS: Sacubitril/valsartan should be effective on pathophysiologic mechanisms and cardiovascular outcomes of Marfan syndrome-related cardiovascular complications.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsHeart FailureHumansMaleMarfan SyndromeTetrazolesTreatment OutcomeValsartanYoung AdultAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Identifiers

PMID31764806
PMCPMC6882602
OpenAlexW2991554798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.